Open AccessREMOTE RESULTS OF SUBLINGUAL ALLERGENSPECIFICIMMUNOTHERAPY AT POLLINOSIS PATIENTS - FIVE YEARS'RESEARCH
Author(s) -
M V Manzhos,
Е С Феденко,
M. A. Мyagkova,
G A Keropyan,
S A Shkadov,
A I Peretrukhin,
M V Manzhos,
Е С Феденко,
M. A. Мyagkova,
G A Keropyan,
S A Shkadov,
A I Peretruhin
Publication year - 2011
Publication title -
rossijskij allergologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2686-682X
pISSN - 1810-8830
DOI - 10.36691/rja788
Subject(s) - medicine , slit , discontinuation , sublingual immunotherapy , asthma , allergen , dust mites , sublingual administration , allergy , pediatrics , immunology , genetics , biology
Background. The purpose of the work was to investigate remote and preventive results of sublingual allergenspecificimmunotherapy (SLiT) at pollinosis patients.Methods. 25 patients at the age from 19 till 50 years old with an allergic rhinitis and asthma (35%) sensitized toartemisia were under the supervision. SLiT was administered in the period since September 2003 till May 2006with pollen allergen («Sevapharma», Czech Republik). The average total dose of the allergen per one patientat the end of the third year was 189999 PNU. Clinical efficiency was estimated annually and in 30 months afterdiscontinuation of SLiT. Frequency and intensity of symptoms during the pollen season, requirement for medicines,FEV1 parameters and results of prick tests were considered.Results. good and excellent results after three courses of immunotherapy demonstrated 23 patients (92%), satisfactory- 2 patients (8%). The results were remained at 22 patients (88%) within the next 30 months. at 3 patients(12%) increase of rhinoconjunctivitis symptoms was noted, and 3 (12%) showed expansion of a sensibilisationspectrum. Further increase of intensity and frequency of asthma symptoms, decrease in indicators FEV1 was notregistered.Conclusion. SLiT is a highly effective method of treatment for patients with seasonal rhinitis and leads to theclinical results remaining more than 2 years at the majority of patients.